ArticleNucleic acids research2022
Structure and mechanism of the type I-G CRISPR effector.
Article in Nucleic acids research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Target discrimination and PAM profiling of the Thermotoga maritima type I-B CRISPR system.The Biochemical journal · 2026Article
- Structural basis of Cas8-independent Cas3 recruitment in Type I-F2 CRISPR-Cas.Nucleic acids research · 2026Article
- Enhanced editing ofApplied and environmental microbiology · 2026Article
- A type III-associated Cas6 functions as a negative regulator of type I-B CRISPR-Cas system in Thermus thermophilus.Communications biology · 2025Article
- Biochemical plasticity of the Escherichia coli CRISPR Cascade revealed by in vitro reconstitution of Cascade activities from purified Cas proteins.The FEBS journal · 2024Article
- Structural basis for the type I-F Cas8-HNH system.The EMBO journal · 2024Article
- Structure and genome editing of type I-B CRISPR-Cas.Nature communications · 2024Article
- Type III-B CRISPR-Cas cascade of proteolytic cleavages.Science (New York, N.Y.) · 2024Article
- Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.Molecular cell · 2024Article
- Repurposing the atypical type I-G CRISPR system for bacterial genome engineering.Microbiology (Reading, England) · 2023Article
- Mechanistic insights into DNA binding and cleavage by a compact type I-F CRISPR-Cas system in bacteriophage.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Cold Cas: reevaluating the occurrence of CRISPR/Cas systems inFrontiers in microbiology · 2023Article
- HIV infection detection using CRISPR/Cas systems: Present and future prospects.Computational and structural biotechnology journal · 2023Review
- Type I CRISPR-Cas-mediated microbial gene editing and regulation.AIMS microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Type I CRISPR systems are the most common CRISPR type found in bacteria. They use a multisubunit effector, guided by crRNA, to detect and bind dsDNA targets, forming an R-loop and recruiting the Cas3 enzyme to facilitate target DNA destruction, thus providing immunity against mobile genetic elements. Subtypes have been classified into families A-G, with type I-G being the least well understood. Here, we report the composition, structure and function of the type I-G Cascade CRISPR effector from Thioalkalivibrio sulfidiphilus, revealing key new molecular details. The unique Csb2 subunit processes pre-crRNA, remaining bound to the 3' end of the mature crRNA, and seven Cas7 subunits form the backbone of the effector. Cas3 associates stably with the effector complex via the Cas8g subunit and is important for target DNA recognition. Structural analysis by cryo-Electron Microscopy reveals a strikingly curved backbone conformation with Cas8g spanning the belly of the structure. These biochemical and structural insights shed new light on the diversity of type I systems and open the way to applications in genome engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.